KCT0004207尚未招募不适用
Ibrutinib for relapsed or refractory mantle cell lymphoma: multicenter retrospective analysis
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •Patients with MCL diagnosed by a pathologist (based on the WHO 2017 classification)
- •1) mantle cell lymphoma
- •2) leukemic nonnodal mantle cell lymphoma
- •3) in situ mantle cell neoplasia
- •- Aged = 19 years
- •- Relapsed or refractory patients treated with ibrutinib, including relapse after autologous stem cell transplantation
排除标准
- •Patients whose clinical and pathological data are not available
- •Patients who were not treated with ibrutinib
研究者
相似试验
已完成
不适用
Ibrutinib for Relapsed or Refractory Mantle Cell LymphomaMantle Cell LymphomaNCT04061850Samsung Medical Center88
终止
1 期
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell LymphomaMantle Cell LymphomaNCT02356458Swiss Group for Clinical Cancer Research58
Approved For Marketing
不适用
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaRelapsed or Refractory Mantle Cell LymphomaNCT01833039Janssen Biotech, Inc.
进行中（未招募）
2 期
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaCCND1 PositiveCCND2 PositiveCCND3 PositiveCD20 PositiveRecurrent Mantle Cell LymphomaRefractory Mantle Cell LymphomaMantle Cell LymphomaNCT01880567M.D. Anderson Cancer Center113
进行中（未招募）
不适用
Bendamustine plus rituximab for mantle cell lymphomaDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0005149Samsung Medical Center40